Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013313688> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2013313688 endingPage "222" @default.
- W2013313688 startingPage "218" @default.
- W2013313688 abstract "Some authors have recently reported that maximum androgen block (MAB), in which the nonsteroidal anti-androgen, flutamide, is used together with conventional hormone therapy such as castration or luteinizing hormone-releasing hormone analogue, is more effective for prostate cancer than conventional methods. However, others have reported that the effect of MAB on survival is minimal, and definite conclusions concerning MAB remain unclear. Conversely, using flutamide as a second-line hormone therapy after recurrence is also considered, but few authors have reported whether this therapeutic option is effective or for which patients it is effective.124 patients with prostate cancer were diagnosed and followed at Kobe City General Hospital between 1995 and 1997. Twenty-two of these cases developed recurrence during first-line hormone therapy, and flutamide was prescribed in these cases. The prognostic value and effectiveness of flutamide were evaluated by measurement of serum prostate-specific antigen (PSA) at diagnosis, posttreatment nadir PSA level, PSA at the time of flutamide use, histological grade, recurrence-free time after firstline hormone therapy and age at the time of diagnosis.Six of 9 cases whose post-treatment nadir PSA levels after initial hormone therapy were within the normal limit (<4 ng/ml) achieved complete remission (CR) with flutamide use, but no patient whose post-treatment nadir PSA level remained elevated achieved CR. PSA at diagnosis and PSA at the start of flutamide use were significantly lower for patients with CR. However, the results of multivariate logistic regression analysis demonstrated that only the post-treatment nadir PSA level was significantly correlated with prognosis of flutamide use.Flutamide use as second-line hormone therapy should be limited to cases in which first-line hormone therapy has been highly effective and for whom the post-treatment nadir PSA level was within normal limits, and other patients should undergo other therapies. By limiting flutamide use to patients in whom the effect of flutamide is considered to be maximal, the incidence of complications and medication costs can be decreased." @default.
- W2013313688 created "2016-06-24" @default.
- W2013313688 creator A5030468520 @default.
- W2013313688 creator A5050158822 @default.
- W2013313688 creator A5052552300 @default.
- W2013313688 creator A5087094599 @default.
- W2013313688 date "2000-01-01" @default.
- W2013313688 modified "2023-10-17" @default.
- W2013313688 title "Prostate–Specific Antigen Levels and Clinical Response to Flutamide as the Second Hormone Therapy for Hormone–Refractory Prostate Carcinoma" @default.
- W2013313688 cites W1985654792 @default.
- W2013313688 cites W2011120797 @default.
- W2013313688 cites W2014145760 @default.
- W2013313688 cites W2035483156 @default.
- W2013313688 cites W2037229475 @default.
- W2013313688 cites W2038415989 @default.
- W2013313688 cites W2074613446 @default.
- W2013313688 cites W2108955823 @default.
- W2013313688 cites W2117570501 @default.
- W2013313688 cites W2496614195 @default.
- W2013313688 doi "https://doi.org/10.1159/000020121" @default.
- W2013313688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10705202" @default.
- W2013313688 hasPublicationYear "2000" @default.
- W2013313688 type Work @default.
- W2013313688 sameAs 2013313688 @default.
- W2013313688 citedByCount "21" @default.
- W2013313688 countsByYear W20133136882012 @default.
- W2013313688 countsByYear W20133136882013 @default.
- W2013313688 countsByYear W20133136882018 @default.
- W2013313688 countsByYear W20133136882019 @default.
- W2013313688 countsByYear W20133136882021 @default.
- W2013313688 countsByYear W20133136882022 @default.
- W2013313688 crossrefType "journal-article" @default.
- W2013313688 hasAuthorship W2013313688A5030468520 @default.
- W2013313688 hasAuthorship W2013313688A5050158822 @default.
- W2013313688 hasAuthorship W2013313688A5052552300 @default.
- W2013313688 hasAuthorship W2013313688A5087094599 @default.
- W2013313688 hasConcept C121608353 @default.
- W2013313688 hasConcept C126322002 @default.
- W2013313688 hasConcept C126894567 @default.
- W2013313688 hasConcept C143998085 @default.
- W2013313688 hasConcept C2776235491 @default.
- W2013313688 hasConcept C2778313021 @default.
- W2013313688 hasConcept C2779279991 @default.
- W2013313688 hasConcept C2779322244 @default.
- W2013313688 hasConcept C2780192828 @default.
- W2013313688 hasConcept C2780275930 @default.
- W2013313688 hasConcept C2781406297 @default.
- W2013313688 hasConcept C530470458 @default.
- W2013313688 hasConcept C61367390 @default.
- W2013313688 hasConcept C71315377 @default.
- W2013313688 hasConcept C71924100 @default.
- W2013313688 hasConceptScore W2013313688C121608353 @default.
- W2013313688 hasConceptScore W2013313688C126322002 @default.
- W2013313688 hasConceptScore W2013313688C126894567 @default.
- W2013313688 hasConceptScore W2013313688C143998085 @default.
- W2013313688 hasConceptScore W2013313688C2776235491 @default.
- W2013313688 hasConceptScore W2013313688C2778313021 @default.
- W2013313688 hasConceptScore W2013313688C2779279991 @default.
- W2013313688 hasConceptScore W2013313688C2779322244 @default.
- W2013313688 hasConceptScore W2013313688C2780192828 @default.
- W2013313688 hasConceptScore W2013313688C2780275930 @default.
- W2013313688 hasConceptScore W2013313688C2781406297 @default.
- W2013313688 hasConceptScore W2013313688C530470458 @default.
- W2013313688 hasConceptScore W2013313688C61367390 @default.
- W2013313688 hasConceptScore W2013313688C71315377 @default.
- W2013313688 hasConceptScore W2013313688C71924100 @default.
- W2013313688 hasIssue "2" @default.
- W2013313688 hasLocation W20133136881 @default.
- W2013313688 hasLocation W20133136882 @default.
- W2013313688 hasOpenAccess W2013313688 @default.
- W2013313688 hasPrimaryLocation W20133136881 @default.
- W2013313688 hasRelatedWork W1604671744 @default.
- W2013313688 hasRelatedWork W1992657261 @default.
- W2013313688 hasRelatedWork W2034243780 @default.
- W2013313688 hasRelatedWork W2038565121 @default.
- W2013313688 hasRelatedWork W2119114732 @default.
- W2013313688 hasRelatedWork W2127440557 @default.
- W2013313688 hasRelatedWork W2148869351 @default.
- W2013313688 hasRelatedWork W2897445903 @default.
- W2013313688 hasRelatedWork W3129209394 @default.
- W2013313688 hasRelatedWork W4281788288 @default.
- W2013313688 hasVolume "37" @default.
- W2013313688 isParatext "false" @default.
- W2013313688 isRetracted "false" @default.
- W2013313688 magId "2013313688" @default.
- W2013313688 workType "article" @default.